Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excited By Unique Capabilities Of Zydus Cadila, Eli Lilly Partners For Research In Cardiovascular Drugs

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After striking collaborative research deals with India's Piramal Life Sciences, Jubilant Organosys and Suven, U.S. drug giant Eli Lilly has added Zydus Cadila as its latest partner for drug discovery and development of new cardiovascular treatments
Advertisement

Related Content

Asia Spotlight: FDA Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners
Asia Spotlight: FDA Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners
Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
Eli Lilly's China R&D Head Tony Zhang On Looking At The Universe Of Possibilities In China: An Interview With PharmAsia News
Eli Lilly's China R&D Head Tony Zhang On Looking At The Universe Of Possibilities In China: An Interview With PharmAsia News
Eli Lilly Global External R&D Director Yetunde Taiwo On Partnering Plans For Discovery Research: An Interview With PharmAsia News
India’s Jubilant, Eli Lilly In Joint Venture To Develop Molecules
Advertisement
UsernamePublicRestriction

Register

SC071203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel